Survodutide Shows Promising Weight Loss and Cardiometabolic Benefits
Survodutide is a new investigational dual GLP-1 injectable medication being tested for weight management in clinical trials.
Survodutide is a once-weekly injectable medication being developed by Zealand and Boehringer Ingelheim for obesity as well as nonalcoholic steatohepatitis (NASH), a type of liver disease.
In clinical trials, survodutide – a GLP-1/glucagon dual receptor agonist – led to significant weight loss for people living with obesity. If you take a GLP-1 medicine for blood sugar or weight management, you've probably heard how important it is to avoid muscle loss through healthy nutrition and physical activity. Newly shared 2026 results suggest it may also be effective at preserving muscle mass while also reducing visceral fat, which can increase the risk of insulin resistance, heart disease, and type 2 diabetes, among other health conditions.
What does the research say?
The latest 2026 research found that participants with overweight or obesity taking survodutide experienced nearly 17% weight loss (an average of 39 pounds) after 76 weeks of treatment. Full results are expected to be shared at the American Diabetes Association conference in June.
Past studies found that clinical trial participants taking survodutide for obesity experienced up to 19% in weight loss over 46 weeks. The phase 2 study included 387 adults living with overweight or obesity who did not have diabetes. At baseline, the average age was about 49 years with a body mass index (BMI) of 37. Over 46 weeks, survodutide led to weight loss of up to 19%. Weight loss ranged from approximately 16 pounds for the lowest dose of survodutide to 43 pounds for the highest dose. Survodutide also led to improvements in cardiometabolic health, such as reduced blood pressure and waist circumference.
Lead trial investigator Dr. Carel le Roux from the University College Dublin in the U.K. noted that the weight loss didn’t appear to plateau at the end of the study, which suggests that patients could see additional weight loss in longer studies. Along with chronic weight management, le Roux also described improvements in heart health:
- Participants on the highest dose of survodutide saw an average reduction in waist circumference of approximately six inches. To put this in perspective, this weight reduction amounts to about “four beltholes,” le Roux said.
- Participants on survodutide doses of 2.4 mg or greater saw substantial reductions in blood pressure, which could indicate benefits for cardiovascular risk factors.
Overall, le Roux said survodutide was reasonably well-tolerated. As with other GLP-1-based therapies, the most common adverse effects of survodutide are gastrointestinal. As with any drug treatment, there can be a risk for allergic reactions.
What do these results mean?
The new data suggest that survodutide is a promising investigational treatment for weight management, with weight loss similar to other dual agonist medications like Mounjaro (tirzepatide).
In another clinical trial in people with type 2 diabetes, survodutide was shown to improve A1C by up to 1.88 percentage points after 16 weeks in the group receiving the highest dose (1.8 mg), injected twice a week. The reductions in blood pressure in this initial trial also suggest that survodutide may benefit heart health and prevent cardiovascular disease in the long term, as Wegovy (semaglutide) has demonstrated. These findings are important in the context of overall well-being beyond a number on a scale.
“It’s not just weight loss, but really health gain that we should think about,” le Roux said.
With the success of these new types of therapies, people with obesity will have more treatment options to choose from. Ultimately, researchers envision a future for obesity treatment similar to that for high blood pressure or cholesterol, where patients and providers can choose from a variety of different treatments to reach their ideal body weight.
Learn more about GLP-1 medications here: